Spots Global Cancer Trial Database for Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Official Title: Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study
Study ID: NCT05970627
Study Description
Brief Summary: This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Huzhou Central Hospital, Huzhou, Zhejiang, China
Lishui Central Hospital, Lishui, Zhejiang, China
Ningbo First Hospital, Ningbo, Zhejiang, China
Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
Ningbo Second Hospital, Ningbo, Zhejiang, China
Taizhou Hospital, Taizhou, Zhejiang, China
Contact Details
Name: Jiren Yu
Affiliation: First Affiliated Hospital of Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
